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Introduction {#sec1}
============

Obesity is a chronic disease involving an excessive amount of adipose tissue that increases the body weight and induces deleterious consequences for metabolic health ([@bib27]). Two types of adipose tissue exist in mammals, which are white adipose tissue (WAT) and brown adipose tissue (BAT). WAT principally functions in the energy storage through lipid accumulation, whereas BAT breaks down lipids to generate heat via uncoupling protein 1 (UCP1)-mediated non-shivering thermogenesis ([@bib28]). In addition to the classic white and brown adipocytes, another metabolic phenotype, the beige (also called brite for "brown in white") adipocytes have also been identified in certain depots of WAT with similar characteristics to BAT, in particular the capacity for uncoupled respiration and breakdown of lipids ([@bib20]) ([@bib26]) ([@bib34]). Although BAT was previously considered to be restricted to infants and small animals, the recent discovery of BAT in human adults stimulated the research interests in increasing energy expenditure by activation of BAT and recruitment of beige adipocytes (termed "browning"). Browning is therefore considered a potential strategy to modulate energy balance and improve metabolic health ([@bib16]) ([@bib19]).

Considerable attention has been given to the potential of increasing adipose tissue thermogenesis as a way of combating obesity development. Therapeutic perspectives can be expected from the use of pharmacotherapeutic agents that induce adipose browning, such as stimulation of BAT-specific UCP1 and enhancement of oxidative metabolism in WAT. UCP1 has long been considered a key factor in regulation of non-shivering thermogenesis and body adiposity, but one potential risk of UCP1 overexpression in WAT is excessive heat production, which may result in hyperthermia ([@bib35]) ([@bib25]). The identification of UCP1-independent thermogenic mechanisms therefore attracts considerable attention in recent years. A variety of signaling pathways and genes involved in the regulatory control of beige adipocytes have been discovered with many browning agents evaluated *in vitro* or in rodent models *in vivo* ([@bib5]) ([@bib22]) ([@bib24]). We have previously reported that the Notch signaling pathway is critical in regulation of adipose browning as well as energy homeostasis ([@bib4]). It was found that inhibition of Notch signaling through administration of a γ-secretase inhibitor dibenzazepine (DBZ) resulted in browning of WAT, decreased body fat mass, and improved systemic metabolism in obese mice ([@bib5]). Moreover, sustained Notch inhibition and enhanced anti-obesity therapeutic efficacy in obese mice could be further achieved through encapsulating the drug into polymeric particles ([@bib15]) ([@bib14]).

Rodent models have long been the pillar of obesity studies, because they are inexpensive to maintain, have a sequenced genome, and are easily modified by genetic engineering. However, disparate results in metabolism and physiology between rodents and humans have undoubtedly complicated the translation of fundamental research findings into therapeutic interventions for obesity ([@bib33]). Also, it remains unknown whether the metabolic benefits of Notch inhibition are dependent on UCP1-mediated thermogenesis and evolutionarily relevant in other mammalian species. The pig is emerging as an alternative biomedical model for investigating energy metabolism and obesity, particularly for UCP1-independent thermogenic mechanisms, due to the presence of excessive WAT and absence of functional BAT postnatally resulting from the lack of UCP1 protein in the domestic pig lineage ([@bib13]) ([@bib3]). Furthermore, the pig also has similar metabolic features and cardiovascular system as well as proportionally similar organ sizes to humans ([@bib33]).

Herein, we report that inhibition of Notch signaling pathway promotes beige adipocyte-specific gene expression and mitochondrial biogenesis, as well as reduces adiposity in pigs *in vivo*. We chose poly(lactide-*co*-glycolide) (PLGA) as the carrier matrix, as it is a widely used polymer for fabricating nanoparticles (NP) due to its excellent biodegradability and biocompatibility, well-documented utility for sustained drug release, and approval by FDA for human use in a number of therapeutic devices ([@bib17]). The development of PLGA NPs further enhances the efficacy of intracellular drug delivery to the adipocytes within specific subcutaneous WAT depots in pigs, allowing the encapsulated Notch inhibitor to sustain its pharmacological action over a prolonged period of time. These findings provide insights into the contribution of Notch inhibition in the metabolism of adipose tissue in a large animal model and highlight the therapeutic potential of targeting Notch signaling in obesity treatment.

Results {#sec2}
=======

DBZ Promotes Beige Adipogenesis and Mitochondrial Thermogenesis in Porcine Adipocytes through Inhibition of Notch Signaling *In Vitro* {#sec2.1}
--------------------------------------------------------------------------------------------------------------------------------------

To determine the role of Notch signaling in porcine adipogenesis, DBZ was used to inhibit γ-secretase that is essential for the activation of Notch signaling through mediating the cleavage of Notch intracellular domain (NICD). Preadipocytes isolated from subcutaneous fat of young pigs were treated with DBZ (10 μM) or vehicle control (DMSO, 0.1% v/v) after induced to differentiate. As shown in [Figure 1](#fig1){ref-type="fig"}A, differentiation of porcine adipocytes was efficiently induced with lipid droplets formed after incubation with induction medium for five days followed by differentiation medium for four days. Both phase contrast and oil red O staining images confirmed that the number of lipid droplets increased in the DBZ-treated cells compared with the vehicle control group, suggesting that the treatment with DBZ enhanced the differentiation efficiency of porcine preadipocytes. However, there were no obvious differences in the size of lipid droplets between two groups. Total lipid content within the cells was further measured by quantitative analysis of oil red O intensity. The results showed that the absorbance value of oil red O extracted from the DBZ-treated cells was 1.18-fold higher than that in the control group ([Figure 1](#fig1){ref-type="fig"}B, p ≤ 0.01), demonstrating that DBZ promoted the differentiation of porcine preadipocytes and accumulation of lipid droplets.Figure 1DBZ Promotes Beige Adipogenesis and Mitochondrial Thermogenesis in Porcine Adipocytes through Inhibition of Notch Signaling *In Vitro*(A) Phase contrast and bright field images of differentiated porcine adipocytes stained with oil red O.(B) Relative absorbance of oil red O extracted from stained porcine adipocytes.(C) Real-time qPCR analysis showing the mRNA levels of Notch target (HES1), adipogenic (FABP4 and PGC1α), and beige-fat-selective genes (CIDEA and DIO2).(D) Western blot results showing the protein expression levels of adipogenic (FABP4, PPARγ, and C/EBPα) and lipolytic (ATGL) markers as well as mitochondrial OXPHOS in differentiated porcine adipocytes treated with DBZ.(E and F) Quantification of protein expression levels of adipogenic (FABP4, PPARγ, and C/EBPα) and lipolytic (ATGL) markers (E) and mitochondrial OXPHOS (F) normalized to β-Actin controls by densitometry analysis.

We also examined the gene expression in DBZ and vehicle control treated porcine adipocytes using real-time qPCR. The mRNA expression of HES1, a Notch downstream target gene, was significantly inhibited after the DBZ treatment (p ≤ 0.05), suggesting efficient inhibition of Notch signaling. Importantly, the expression of adipogenic and beige-fat-selective genes, including fatty acid binding protein 4 (FABP4, p ≤ 0.05), peroxisome-proliferator-activated receptor gamma coactivator 1-alpha (PGC1α, p ≤ 0.05), and cell-death-inducing DNA fragmentation factor alpha-like effector A (CIDEA, p ≤ 0.01), were all significantly upregulated in the DBZ-treated cells ([Figure 1](#fig1){ref-type="fig"}C). The cells treated with DBZ also expressed a higher mRNA level of type 2 deiodinase (DIO2) than the control; however, the difference was not statistically significant (p \> 0.05). The differentiation and gene expression results together indicate that the DBZ treatment promotes beige adipogenesis through efficient inhibition of Notch signaling pathway.

Consistently, Western blot analysis revealed that the protein expression levels of adipogenic genes, including CCAAT/enhancer-binding protein alpha (C/EBPα, p ≤ 0.001), FABP4 (p ≤ 0.05), and peroxisome-proliferator-activated receptor gamma (PPARγ, p ≤ 0.05) significantly increased after the DBZ treatment ([Figures 1](#fig1){ref-type="fig"}D and 1E). Moreover, the DBZ-treated cells exhibited upregulated protein expression of adipose triglyceride lipase (ATGL, p ≤ 0.01), which is a well-recognized lipolysis rate-limiting enzyme in adipocytes ([Figures 1](#fig1){ref-type="fig"}D and 1E). Adipocyte lipolysis is generally mediated by a complicated process that involves a number of lipases and proteins associated with lipid droplets. Our data suggest that the treatment with DBZ promotes beige adipogenesis and lipolysis synergistically. Furthermore, enhanced protein expression of oxidative phosphorylation (OXPHOS) was also observed in the DBZ group compared with the control, particularly for the complexes II (p ≤ 0.01), IV (p ≤ 0.01), and V (p ≤ 0.005) ([Figures 1](#fig1){ref-type="fig"}D and 1F). These results demonstrate a potential intrinsic association of recruitment of beige adipocytes with mitochondrial biogenesis and oxidative capacity.

PLGA NPs Enable Rapid Cellular Uptake in Porcine Preadipocytes {#sec2.2}
--------------------------------------------------------------

To leverage benefits of polymeric NPs to achieve sustained intracellular drug release, we prepared PLGA NPs using the nanoprecipitation technique ([Figure 2](#fig2){ref-type="fig"}A). The NPs possessed an average particle size of 177 ± 6 nm and a negative surface charge with zeta potential of −20.2 ± 3.0 mV. A high encapsulation efficiency of 94% and sustained drug release for over one week *in vitro* were achieved with optimized parameters ([@bib14]). The morphology of NPs was visualized using transmission electron microscopy (TEM). NPs demonstrated a spherical shape with a particle size ranging from 100 nm to 200 nm, which was consistent with the result obtained by dynamic scattering light ([Figure 2](#fig2){ref-type="fig"}A). Cellular internalization of NPs was examined by incubating porcine preadipocytes with fluorescent dye Cy5.5-conjugated NPs for different periods of time (i.e. 15 min, 1 h, and 6 h). As shown in [Figure 2](#fig2){ref-type="fig"}B, a punctate and well-dispersed red fluorescent signal originating from Cy5.5-conjugated NPs was detected inside the cells, indicating that NPs have been rapidly taken up by porcine preadipocytes within 15 min. Endocytosis could be the principal mechanism contributing to the superior cellular internalization efficiency of NPs ([@bib14]). When the incubation time of NPs was extended to 1 h, NPs were found to be distributed throughout the entire cytoplasm with a more homogeneous pattern compared with the early time point, which demonstrates the escape of NPs from endocytic vesicles. After 6 h of incubation, the red fluorescent signal in cells remained detectable, but the intensity and distribution pattern were similar to that observed at the 1 h time point, suggesting that cellular uptake of NPs in porcine preadipocytes was saturated within 1 h of incubation period. Our results reveal that NPs can be quickly taken up by primary porcine preadipocytes within 15 min and retained inside the cells for a prolonged period of time. Therefore, NP-mediated drug delivery can potentially reduce the frequency of administration and allow the encapsulated drug to sustain its pharmacological action.Figure 2PLGA NPs Enable Rapid Cellular Uptake in Porcine Preadipocytes(A) DBZ-encapsulated NPs prepared by the nanoprecipitation technique showing a spherical shape with a particle size ranging from 100 nm to 200 nm.(B) *In vitro* cellular uptake of Cy5.5-conjugated NPs in primary porcine preadipocytes after 15 min, 1 h, and 6 h of incubation.

DBZ-Loaded NPs Inhibit Notch Signaling, Promote Beige Adipogenesis and Mitochondrial Biogenesis in Porcine Adipocytes *In Vitro* {#sec2.3}
--------------------------------------------------------------------------------------------------------------------------------

Primary porcine preadipocytes were treated with DBZ-encapsulated NPs at a final NP concentration of 0.1 mg/mL on the first and fifth days of differentiation. As shown in [Figure 3](#fig3){ref-type="fig"}A, more lipid droplets were embedded and accumulated in the cytoplasm of adipocytes treated with DBZ-loaded NPs than the control group treated with blank NPs, suggesting that DBZ enhances the differentiation efficiency of porcine preadipocytes. Total lipid content within the cells was also quantified by measuring the absorbance of oil red O extracted from stained adipocytes. The absorbance value in the group treated with DBZ-encapsulated NPs was 1.58-fold higher than that in the blank NP group ([Figure 3](#fig3){ref-type="fig"}B, p ≤ 0.005). This finding indicates that efficient intracellular delivery and release of DBZ are achieved through rapid cellular internalization of NPs to promote the differentiation of porcine preadipocytes and accumulation of lipid droplets. It was also noted that the enhancement of cell differentiation achieved by the short-time incubation of DBZ-encapsulated NPs (i.e. 1.58-fold increase) was more robust than the treatment with native DBZ (i.e. 1.18-fold increase) at comparable drug concentrations. These results demonstrate that encapsulation of hydrophobic DBZ into NPs enables controlled drug delivery and target the agent toward the cells of interest, thereby improving its bioavailability and therapeutic efficacy.Figure 3DBZ-Loaded NPs Inhibit Notch Signaling, Promote Beige Adipogenesis, and Mitochondrial Biogenesis in Porcine Adipocytes *In Vitro*(A) Phase contrast and bright field images of differentiated porcine adipocytes stained with oil red O.(B) Relative absorbance of oil red O extracted from stained adipocytes.(C) Real-time qPCR analysis showing the mRNA levels of Notch target (HES1), adipogenic (FABP4, PPARγ, and PGC1α), beige-fat-selective genes (CIDEA and DIO2), and mitochondrial marker genes (COX1 and COX5B).(D) Western blot results showing the protein expression levels of adipogenic (FABP4, PPARγ, and C/EBPα) and lipolytic (ATGL) marker genes in differentiated porcine adipocytes treated with DBZ loaded NPs.(E) Quantification of protein expression levels of adipogenic (FABP4, PPARγ, and C/EBPα) and lipolytic (ATGL) markers normalized to β-Actin controls by densitometry analysis.

[Figure 3](#fig3){ref-type="fig"}C illustrates the changes in mRNA expression of Notch target, adipogenic, and beige-fat-selective genes in differentiated adipocytes following the treatment with DBZ-loaded NPs. The treatment with DBZ-encapsulated NPs significantly inhibited the mRNA expression of HES1 (p ≤ 0.01), whereas increased the mRNA expression of adipogenic and beige-fat-selective genes, including FABP4 (p ≤ 0.05), PPARγ (p ≤ 0.05), PGC1α (p ≤ 0.005), CIDEA (p ≤ 0.05), and DIO2 (p ≤ 0.01), which was consistent with the results shown in [Figure 1](#fig1){ref-type="fig"}C. Moreover, the mRNA expression levels of mitochondria-related genes, such as cytochrome c oxidase (COX) 1 and 5B, were also upregulated after the treatment of DBZ-loaded NPs compared with the control group. Particularly, the change in COX1 expression was statistically significant (p ≤ 0.05). Previous studies have shown that stimulation of COX activity is a key initiator for the recruitment of beige adipocytes ([@bib21]). COX produces prostaglandins or related products that promote mitochondrial biogenesis and increase the uncoupling capacity upon activation by norepinephrine or cold acclimatization ([@bib2]). Overall, these results indicate that the released DBZ from NPs maintains its biological activity to promote beige adipogenesis and mitochondrial oxidative metabolism through efficient and sustained inhibition of Notch signaling pathway.

The changes in protein expression were analyzed by western blotting with results shown in [Figures 3](#fig3){ref-type="fig"}D and 3E. Similar to the result of native DBZ treatment, the protein levels of adipogenic genes, including FABP4 (p ≤ 0.005), PPARγ (p ≤ 0.005), and C/EBPα (p ≤ 0.05), significantly increased after the treatment with DBZ-loaded NPs. The expression of ATGL was also investigated to determine whether inhibition of Notch signaling was involved in regulation of other lipid metabolism activities, such as lipolysis that provides fuel for thermogenesis ([@bib29]). The differentiated porcine adipocytes treated with DBZ-loaded NPs exhibited an upregulated protein expression level of ATGL compared with that in the control group (p ≤ 0.05), indicating promoted lipolytic activities of porcine adipocytes. Taken together, our results demonstrate that DBZ-encapsulated NPs are quickly taken up by primacy porcine preadipocytes within 1 h and retained inside the cells to achieve efficient and sustained inhibition of Notch signaling pathway, thereby promoting beige adipogenesis, mitochondrial biogenesis, and lipolysis for an extended period of time.

Local Injection of DBZ-Loaded NPs Increases the Number of Mitochondria and Multilocular Lipid Droplets in WAT in Pigs {#sec2.4}
---------------------------------------------------------------------------------------------------------------------

To investigate the effect of NP-mediated Notch inhibition on recruitment of beige adipocytes in pigs *in vivo*, we injected blank or DBZ-encapsulated NPs into dorsal subcutaneous WAT of piglets ([Figure 4](#fig4){ref-type="fig"}B). WAT at the injection site was harvested from the pigs after five consecutive weekly administration of NPs ([Figure 4](#fig4){ref-type="fig"}A) and subjected to hematoxylin and eosin (H&E) staining as well as electron microscopy analysis. H&E staining revealed the morphological changes of adipocytes in the WAT depot in pigs ([Figure 4](#fig4){ref-type="fig"}C). WAT in the pigs receiving local injections of DBZ-loaded NPs exhibited a "brown-like" pattern with multilocular lipid droplets and shrinkage of adipocytes, demonstrating recruitment of beige adipocytes. Quantitative analysis of WAT depots also showed significant differences in adipocyte size distribution with an increase in the percentage of small adipocytes (\<500 μm^2^) and a reduction of large adipocyte population (≥1000 μm^2^) ([Figure 4](#fig4){ref-type="fig"}D). Consistently, both TEM ([Figure 4](#fig4){ref-type="fig"}E) and scanning electron microscopy (SEM) ([Figure 4](#fig4){ref-type="fig"}F) analysis confirmed that the number of mitochondria and beige adipocytes showing multilocular droplet structures increased in WAT collected from the pigs injected with DBZ-encapsulated NPs compared with that in the blank-NP-treated pigs. WAT injected with DBZ-loaded NPs also contained a number of small lipid droplets, whereas the size of lipid droplets in WAT injected with blank NPs was relatively large and homogeneous. The presence of small lipid droplets indicate that adipocyte lipolysis might be enhanced in the local WAT depot following the treatment with DBZ-encapsulated NPs.Figure 4Local Injection of DBZ-Loaded NPs Increases the Number of Mitochondria and Multilocular Lipid Droplets in WAT in Pigs(A) Experimental design showing the timeline of NP treatment in piglets.(B) Picture showing the injection site on the shoulder of piglets.(C) Representative images of H&E staining of WAT collected from the pigs after the treatment with blank or DBZ-loaded NPs.(D) Quantitative size analysis of WAT adipocytes from the pigs treated with blank or DBZ-loaded NPs; 700--800 adipocytes in total from three pigs were analyzed for each group.(E and F) Representative TEM (E) and SEM (F) images of porcine WAT after the treatment with blank or DBZ-loaded NPs. White asterisks and arrows mark mitochondria and multilocular lipid droplets in adipocytes, respectively.

Discussion {#sec3}
==========

The Notch signaling pathway plays an important role in cell-cell communication and cell-fate determination during development. It is required for cellular homeostasis in virtually every metabolic organ, including skeletal muscle and adipose tissue ([@bib4]). Our previous studies have discovered that Notch signaling regulates browning of WAT in mice ([@bib5]). However, it remains unknown whether the metabolic benefits of Notch inhibition are dependent on UCP1 and evolutionarily relevant in other mammalian species, particularly large animals. This present work reveals a previously unrecognized role of Notch signaling in the regulatory control of beige fat in pigs, a species that lacks a functional UCP1 protein due to deletion of exons 3--5 in the UCP1 gene ([@bib3]). Molecular, cellular, and histological evidence were provided to demonstrate that pharmacological inhibition of Notch signaling promotes beige adipogenesis and mitochondrial biogenesis as well as reduces adiposity in WAT in pigs. Because Notch signaling is a highly conserved pathway in mammals, it is anticipated that these findings in mice and pigs will be applicable to humans, although further studies investigating the role of Notch signaling in human adipose tissue and its impact on obesity treatment are necessary.

We found that the treatment with a γ-secretase inhibitor DBZ promoted differentiation of porcine preadipocytes *in vitro*. DBZ at a concentration of 10 μM significantly inhibited mRNA expression of HES1 and upregulated adipogenic markers at both transcription and expression levels. The treatment also resulted in increased expression of lipolytic and beige-fat-selective genes. Generally, free fatty acids produced by lipolysis are catalyzed to form acetyl coenzyme A, which enters the mitochondria to participate in β-oxidation and generate heat ([@bib8]). This is the major pathway for the degradation of fatty acids and is associated with mitochondrial content and respiratory capability ([@bib7]). These observations suggest Notch inhibition promotes beige adipogenesis, lipolysis, and mitochondrial biogenesis in porcine white adipocytes. The Delta-like and Serrate/Jagged family of membrane bound ligands bind to transmembrane Notch receptors, which induces γ-secretase-mediated proteolytic cleavage of Notch and subsequently results in the nuclear translocation of NICD. Once NICD is located in the nucleus, it activates the recombination signal-binding protein for immunoglobulin kappa J region transcriptional complex along with its downstream targets, such as the HES family genes ([@bib30]). Our previous results have shown that the Notch signaling plays a critical role in regulation of adipose browning with pharmacological inhibition of Notch signaling promoting beige adipogenesis and ameliorating obesity in obese mice ([@bib5]). The underlying mechanism is that the Notch downstream target gene HES1 directly binds to the promoter regions of PR-domain-containing 16 (PRDM16) and PGC1α to repress their transcription. These two genes have previously been identified as master regulators of beige adipogenesis and mitochondrial biogenesis ([@bib1]) ([@bib31]). Because the Notch signaling is a highly conserved pathway, it is believed that its functions in regulation of metabolism could be potentially extended to large animals.

UCP1 has long been considered the key thermogenic protein mediating non-shivering thermogenesis and playing a crucial role in regulation of adipose conversion ([@bib23]) ([@bib32]). However, some studies in transgenic rodent models show unexpected results with regard to the metabolic phenotypes between beige-adipocyte-deficient and UCP1-deficient mice. Specifically, beige-adipocyte-deficient mice induced by the adipocyte-specific deletion of PRDM16 developed obesity even under ambient temperature conditions, whereas UCP1 knockout mice displayed obese phenotypes only when they were kept at thermoneutrality ([@bib6]) ([@bib9]). The difference in metabolic phenotypes between these mouse models therefore implies the existence of UCP1-independent thermogenic mechanisms. More recently, calcium cycling has been determined to regulate beige thermogenesis independently of UCP1 ([@bib12]). Creatine-based futile cycle was also found to be an important mechanism of thermoregulation, independent of UCP1 ([@bib18]). The discovery of UCP1-independent thermogenic mechanisms may open up possibilities for improvement of metabolic health, particularly in the elderly who do not possess UCP1-positively expressed adipocytes. In this present work, the role of Notch signaling pathway in regulation of beige fat recruitment was investigated in the pig, which is a unique animal model for obesity research due to the lack of functional UCP1 protein and similarities of metabolic features to humans ([@bib33]) ([@bib13]). Our results confirm that inhibition of Notch signaling promotes the differentiation, beige adipogenesis, and mitochondrial biogenesis in porcine adipocytes despite their lack of the UCP1 protein.

Despite great potential of pharmacological inhibition shown in regulation of beige thermogenesis, translation of this therapeutic strategy for obesity treatment in the clinical settings could be hindered by the potential risks of off-target consequences, lack of control over the location, and acute toxicity induced by high dosage. Frequent injections aiming to maintain the effective therapeutic concentration also might result in unwanted side effects and patient compliance issue. Over the past decades, the field of nanomedicine has evolved alongside the increasing technical needs to enhance the delivery efficiency of various therapeutics, including anti-obesity drugs ([@bib10]). NP delivery systems offer both temporal and spatial control of drug release. There are a number of considerations when developing these NP formulations. For instance, cellular uptake, transport, and fate of NPs are strongly dependent on their physicochemical properties ([@bib36]). Acquirement of well-ordered and dispersed NPs with a highly predictable and desirable size as well as surface characteristics is therefore critical to achieve efficient intracellular delivery of NPs. In our studies, the small particle size and negative surface charge of NPs produced by an optimized nanoprecipitation process could facilitate diffusive mobility and strong repulsive interaction between particles, thus preventing agglomeration and stabilizing NP dispersions. The optimized NPs exhibited rapid cellular internalization in porcine preadipocytes through endocytotic trafficking followed by an endo-lysosome escape to the cytosol, allowing for prolonged intracellular retention and sustained DBZ release for over one week under the physiological condition ([@bib14]). Sustained release NP formulations can also help improve patient compliance by minimizing dose frequency. For effective treatment of chronic diseases, such as obesity, a prolonged release behavior can maintain the therapeutic dose for longer periods of time, minimizing both underexposure and the risk of toxicity from overexposure ([@bib17]). In this work, the encapsulated DBZ was gradually transported out of NPs via diffusion or released from the polymer matrix upon degradation after taken up by porcine preadipocytes. The slowly released DBZ well maintained its bioactivity to achieve sustained inhibition of Notch signaling pathway during preadipocyte differentiation, as evidenced by the efficient downregulation of Notch target gene and resultant elevation of adipogenic, lipolytic, beige-fat-selective, and mitochondrial gene expression. More importantly, direct injection of DBZ-encapsulated NPs into the subcutaneous WAT depots in pigs resulted in efficient and site-specific delivery of Notch inhibitors. The WAT injected with DBZ-loaded NPs exhibited considerable morphological changes with an increased number of mitochondria and multilocular lipid droplets. Local injection into the target tissue is a promising approach to achieve site specificity, permit a reduction in dosage, and avoid drug diffusion to the other off-target organs ([@bib10]) ([@bib15]) ([@bib14]). In addition, slowly released drugs from NPs could allow sustained inhibition of Notch signaling over an extended period of time, thereby improving the therapeutic efficacy and reducing the need for frequent injections as well as potential risks of side effects. These *in vivo* observations are consistent with our *in vitro* results, demonstrating that both recruitment of beige adipocytes and mitochondrial biogenesis in WAT in pigs are promoted by inhibition of Notch signaling through efficient intracellular delivery of DBZ-loaded NPs.

Overall, we have shown that pharmacological inhibition of Notch signaling pathway through administration of DBZ promotes beige adipogenesis and mitochondrial biogenesis in adipocytes of pigs, which lack of functional UCP1 protein. Encapsulation of DBZ into a synthetic PLGA-based nanoparticulate delivery system enables rapid cellular internalization and controlled drug delivery in adipocytes to achieve efficient and sustained Notch inhibition, thereby promoting beige adipogenesis, thermogenesis, and lipolysis *in vitro*. More importantly, injection of DBZ-encapsulated NPs into the subcutaneous WAT depot in pigs leads to localized NP delivery, inducing increased mitochondrial numbers and reduced subcutaneous adipose tissue expansion *in vivo*. This study demonstrates for the first time that Notch signaling is a negative regulator of beige adipocyte biogenesis in a large animal model, highlighting the therapeutic potential of targeting Notch signaling in obesity treatment.

Limitations of the Study {#sec3.1}
------------------------

We have shown that inhibition of Notch signaling pathway promotes beige adipogenesis and mitochondrial biogenesis in pigs that lack functional UCP1 protein. However, the detailed molecular mechanism by which Notch signaling regulates beige thermogenesis remains unknown and is a subject for future research.
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### Lead Contact {#sec3.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Meng Deng (<deng65@purdue.edu>).

### Materials Availability {#sec3.2.2}

All unique/stable reagents generated in this study will be made available on request, but we may require a payment and/or a completed Materials Transfer Agreement if there is potential for commercial application.

### Data and Code Availability {#sec3.2.3}

The original/source data are available from the lead contact on request.
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All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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